Neoadjuvant chemoradiotherapy for locally advanced gastric cancer with bulky lymph node metastasis: Five case reports

Table 1 Preoperative clinicopathological features

Case	Age/(yr)	Sex	Location	Macro-scopic type	cStage	Tumor size/(cm)	S-1/(mg/body per day), radiation	NACRT-related toxicity	Histology	Effect
1	80	M	UM, less, L, Gre	Type 3, type 2	T4a, N2, M0, StageIIIb	5.0 6.0	100, 45 Gy		Tub2, tub1	PD
2	77	M	LM, Post	Tyep 3	T4b, N2, M0, StageIIIc	5.5	100-80, 50 Gy	Diarrhea (grade 2)	Tub2	PR
3	71	F	U, Post	Type 3	T4b, N2, M0, StageIIIc	7.0	80, 30 Gy, XP-HER; 2 Kr		Tub1	SD
4	67	M	LM, Circ	Type 3	T4a, N3, M0, StageIIIb	5.5	120, 30 Gy	Anorexia (grade 3)	Tub1	PR
5	74	F	ML, Post	Type 2	T4a, N2, M0, StageIIIb	5.0	100, 30 Gy	Anorexia (grade 3)	Tub2	PR

S-1: Tegafur/gimeracil/oteracil; NACRT: Neoadjuvant chemoradiotherapy; PD: Progressive disease; PR: Partial response; XP-HER: Capecitabine (Xeloda), cisplatin and trastuzumab (Herceptin); SD: Stable disease.

Table 2 Postoperative clinicopathological features

Case	Operation	Operation time/(min), blood loss/(mL)	Residual tumor	Histological results	Pathologic response	Complication	Survival/(mo)	Recurrence
1	Total gastrectomy	365, 691	R0	ypT1b, N0, M0	Grade 3		Alive (56)	None
2	Distal gastrectomy	278, 789	R0	ypCR, N0, M0	Grade 3		Dead (18)	8M: Peritoneal, dissemination, lung metastasis
3	Total gastrectomy, combined resection of pancreas (body, tail) and spleen	406, 280	R0	ypT3, N1, M0	Grade 1a		Alive (45)	None
4	Distal gastrectomy	310, 700	R0	ypT1a, N2, M0	Grade 2	Chole-cystitis	Alive (41)	None
5	Distal gastrectomy	239, 416	R0	ypCR, N1, M0	Grade 3		Alive (22)	None

R0: No residual tumor; yp: Pathologic classification after preoperative therapy.